<!DOCTYPE html>
<html lang="en"><head>
<script src="Lecture1_files/libs/clipboard/clipboard.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/tabby.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/popper.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="Lecture1_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-html/quarto-syntax-highlighting-a67ac2868200dddf7a4f0e3ae403775c.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<link href="Lecture1_files/libs/quarto-contrib/fontawesome6-0.1.0/all.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-contrib/fontawesome6-0.1.0/latex-fontsize.css" rel="stylesheet">
<script src="Lecture1_files/libs/quarto-contrib/glightbox/glightbox.min.js"></script>
<link href="Lecture1_files/libs/quarto-contrib/glightbox/glightbox.min.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-contrib/glightbox/lightbox.css" rel="stylesheet"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.9.16">

  <title>lecture1</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
      margin-bottom: 0em;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }  </style>
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/theme/quarto-0563d62cdbbc8706427edc095c1dc872.css">
  <link href="Lecture1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">


<section id="penicillin-and-antibiotic-allergies" class="slide level2" data-background-color="#9B0014">
<h2>Penicillin and Antibiotic Allergies</h2>
<p><br> <br></p>
<center>
<p><strong>Prof.&nbsp;Russell E. Lewis</strong> <br> Department of Molecular Medicine <br> University of Padua</p>
<table class="caption-top">
<colgroup>
<col style="width: 48%">
<col style="width: 51%">
</colgroup>
<tbody>
<tr class="odd">
<td><img data-src="images/dmmunipd_logo.jpeg" width="100"></td>
<td><img data-src="images/unipd_seal_white.svg" width="100"></td>
</tr>
</tbody>
</table>
<p><br> <i class="fa-solid fa-envelope fa-1x" aria-label="envelope"></i> russelledward.lewis@unipd.it <br> <i class="fa-brands fa-github fa-1x" aria-label="github"></i> https://github.com/Russlewisbo<br> Slides and course materials: <a href="https://padovaid.com/">www.padovaid.com</a></p>
</center>
</section>
<section id="objectives" class="slide level2">
<h2>Objectives</h2>
<p><br></p>
<ul>
<li><p>Describe the different types of hypersensitivity reactions based on clinical presentation and immunological mechanisms&nbsp;</p></li>
<li><p>Recognise a patient history that will differentiate between immediate and delayed-type hypersensitivity reactions&nbsp;</p></li>
<li><p>Describe the risk of cross-reactions between various beta-lactam antibiotics&nbsp;</p></li>
<li><p>Describe the principles and contraindications for desensitisation</p></li>
<li><p>Describe the clinical manifestations, diagnosis and management of common non-beta-lactam antibiotic allergies</p></li>
</ul>
</section>
<section id="on-target-vs.-off-target-drug-effects" class="slide level2">
<h2>On target vs.&nbsp;off-target drug effects</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/classification.png" class="lightbox" data-gallery="quarto-lightbox-gallery-1"><img data-src="images/classification.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="macy.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Macy et al., 2023</a>)</span></p>
</div></aside></section>
<section id="variable-cutaneous-presentation-of-allergic-drug-reactions" class="slide level2">
<h2>Variable cutaneous presentation of <br>allergic drug reactions</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:25%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/widespreadmacular.png" class="lightbox" data-gallery="quarto-lightbox-gallery-2" title="widespread macupapular"><img data-src="images/widespreadmacular.png" alt="widespread macupapular"></a></p>
<figcaption>widespread macupapular</figcaption>
</figure>
</div>
</div><div class="column" style="width:25%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/macupapular%20aspect.png" class="lightbox" data-gallery="quarto-lightbox-gallery-3" title="macupapular aspect"><img data-src="images/macupapular%20aspect.png" alt="macupapular aspect"></a></p>
<figcaption>macupapular aspect</figcaption>
</figure>
</div>
</div><div class="column" style="width:25%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/isolated%20foilicular.png" class="lightbox" data-gallery="quarto-lightbox-gallery-4" title="isolated follicular"><img data-src="images/isolated%20foilicular.png" alt="isolated follicular"></a></p>
<figcaption>isolated follicular</figcaption>
</figure>
</div>
</div><div class="column" style="width:25%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/coelscing%20erythema.png" class="lightbox" data-gallery="quarto-lightbox-gallery-5" title="coalescing erythema"><img data-src="images/coelscing%20erythema.png" alt="coalescing erythema"></a></p>
<figcaption>coalescing erythema</figcaption>
</figure>
</div>
</div></div>

<aside><div>
<p>Images: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel</p>
</div></aside></section>
<section id="urticaria-and-angioedema" class="slide level2 smaller">
<h2>Urticaria and angioedema</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-left">
<figure>
<div class="quarto-figure quarto-figure-left">
<figure>
<p><a href="images/urticaria.png" class="lightbox" data-gallery="quarto-lightbox-gallery-6" title="urticaria"><img data-src="images/urticaria.png" class="quarto-figure quarto-figure-left" width="300" alt="urticaria"></a></p>
</figure>
</div>
<figcaption>urticaria</figcaption>
</figure>
</div>
</div><div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/angioendema.png" class="lightbox" data-gallery="quarto-lightbox-gallery-7" title="angioedema"><img data-src="images/angioendema.png" width="600" alt="angioedema"></a></p>
<figcaption>angioedema</figcaption>
</figure>
</div>
</div></div>

<aside><div>
<p>Images: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel</p>
</div></aside></section>
<section id="fixed-drug-eruption" class="slide level2 smaller">
<h2>Fixed drug eruption</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/fixed.png" class="lightbox" data-gallery="quarto-lightbox-gallery-8"><img data-src="images/fixed.png" class="quarto-figure quarto-figure-center" width="500"></a></p>
</figure>
</div>

<aside><div>
<p>Image: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel</p>
</div></aside></section>
<section>
<section id="scar-severe-cutaneous-adverse-reactions" class="title-slide slide level1" data-background-color="#9B0014">
<h1>SCAR: Severe Cutaneous Adverse Reactions</h1>

</section>
<section id="erythema-multiforme-toxic-epidermal-necrolysis-ten" class="slide level2 smaller">
<h2><strong>Erythema multiforme,</strong> <br>Toxic epidermal necrolysis (TEN)</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/ten2.png" class="lightbox" data-gallery="quarto-lightbox-gallery-9"><img data-src="images/ten2.png" class="quarto-figure quarto-figure-center" width="500"></a></p>
</figure>
</div>

<aside><div>
<p>Image: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel</p>
</div></aside></section>
<section id="dress-drug-rash-with-eosinophilia-and-systemic-symptoms" class="slide level2 smaller">
<h2><strong>DRESS: Drug rash with eosinophilia</strong> <br> and systemic symptoms</h2>
<div class="columns">
<div class="column" style="width:40%;">
<ul>
<li><p><strong>Latency:</strong> 2-8 weeks</p></li>
<li><p><strong>Non-specific symptoms:</strong></p>
<ul>
<li>Fever (75%), lymphadenopathy (55-65%)</li>
</ul></li>
<li><p><strong>Hematological abnormalities:</strong></p>
<ul>
<li><p><strong>Eosinophilia &gt; 700 mcL (85-95%)</strong></p></li>
<li><p><strong>Leukocytosis (95%), neutrophilia (78%), monocytosis (69%)</strong></p></li>
<li><p><strong>Atypical lymphocytosis (35-67%)</strong></p></li>
</ul></li>
<li><p><strong>Visceral involvement:</strong></p>
<ul>
<li><p><strong>Liver (53-90%)-cholestatic and/or hepatocellular</strong></p></li>
<li><p><strong>Pulmonary (30%)-shortness of breath, cough</strong></p></li>
<li><p><strong>Cardiac involvement (2-20%)- hypotension, tachycardia, dyspnea, LV dysfunction, myocarditis</strong></p></li>
</ul></li>
</ul>
</div><div class="column" style="width:60%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/dress.png" class="lightbox" data-gallery="quarto-lightbox-gallery-10"><img data-src="images/dress.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>
</div></div>

<aside><div>
<p>Image: UptoDate</p>
</div></aside></section>
<section id="dress-pathophysiology-and-systemic-symptoms" class="slide level2 smaller">
<h2>DRESS: Pathophysiology <br> and systemic symptoms</h2>
<div class="columns">
<div class="column" style="width:40%;">
<ul>
<li><p><strong>Pathophysiology:</strong></p>
<ul>
<li><p>Type IV T-cell activation (CD4+/CD8+) producing TNF-α</p></li>
<li><p>Reactivation of viruses from the Herpesviridae family (eg, HHV-6, HHV-7, Epstein-Barr virus [EBV], cytomegalovirus [CMV]) occurs in up to 75 percent of patients-cause or consequence?&nbsp;</p></li>
<li><p>Some patient human leukocyte antigens are associated with higher risk</p></li>
<li><p>RegiSCAR scoring system is a commonly used tool for diagnosis</p></li>
<li><p>Symptoms may worsen or recur despite drug discontinuation or persisnt, requing immunosuppressive treatment</p></li>
</ul></li>
</ul>
</div><div class="column" style="width:60%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/dress.png" class="lightbox" data-gallery="quarto-lightbox-gallery-11"><img data-src="images/dress.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>
</div></div>

<aside><div>
<p>Image: UptoDate</p>
</div></aside></section>
<section id="classic-high-risk-drugs-for-dress" class="slide level2">
<h2>Classic “high-risk” drugs for DRESS</h2>
<p><br></p>
<ul>
<li><p>Allopurinol</p></li>
<li><p>Aromatic antiepileptic agents (carbamazepine, phenytoin, lamotrigine, …)</p></li>
<li><p>Sulphonamides</p></li>
<li><p>Vancomycin</p></li>
<li><p>Minocycline</p></li>
<li><p>Nevirapine</p></li>
<li><p>Anti-tuberculosis drugs</p></li>
<li><p>Mexiletine</p></li>
</ul>
<p><strong>β-lactams are lower risk</strong></p>
</section>
<section id="stevens-johnson-syndrome" class="slide level2 smaller">
<h2>Stevens-Johnson Syndrome</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/SJ.png" class="lightbox" data-gallery="quarto-lightbox-gallery-12"><img data-src="images/SJ.png" width="721"></a></p>
</div><div class="column" style="width:50%;">
<ul>
<li><p>Drug-sensitized cytotoxic CD8+ T cells mediate keratinocyte necrosis</p></li>
<li><p>TEN has a mortality rate of approximately 30% that can exceed 50% in elderly or immunosuppressed patients</p></li>
<li><p>The severity-of-illness score for TEN (SCORTEN) algorithm facilitates clinical diagnosis and prognostication</p></li>
<li><p>SJS is associated with the maintenance of long-lasting tissue-resident memory T-cell responses in the skin that persist after SCAR, necessitating accurate identification and lifelong avoidance of the culprit antibiotic</p></li>
</ul>
</div></div>

<aside><div>
<p>Image: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel</p>
</div></aside></section>
<section id="acute-generalized-exanthematous-pustulosis-agep" class="slide level2 smaller">
<h2><strong>Acute generalized exanthematous pustulosis (AGEP)</strong></h2>
<ul>
<li><p>AGEP is a drug eruption characterized by an extensive sterile, nonfollicular pustular reaction superimposed on erythematous plaques, with a prominent leukocytosis and neutrophilic dominance</p></li>
<li><p>Most cases of antimicrobial-induced AGEP, such as that caused by β-lactams and quinolones, typically cause symptoms within a day of exposure, whereas other drugs take 7 to 14 days of exposure before symptoms.</p></li>
</ul>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/ten.png" class="lightbox" data-gallery="quarto-lightbox-gallery-13"><img data-src="images/ten.png"></a></p>
</div><div class="column" style="width:50%;">
<p><a href="images/agep.png" class="lightbox" data-gallery="quarto-lightbox-gallery-14"><img data-src="images/agep.png"></a></p>
</div></div>

<aside><div>
<p><span class="citation" data-cites="zhang.liu_2015">(<a href="#/references" role="doc-biblioref" onclick="">Zhang and Liu, 2015</a>)</span></p>
</div></aside></section>
<section id="modified-gell-and-coombs-classification" class="slide level2">
<h2>Modified Gell and Coombs Classification</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/coombs.png" class="lightbox" data-gallery="quarto-lightbox-gallery-15"><img data-src="images/coombs.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="hausmann.etal_2010">(<a href="#/references" role="doc-biblioref" onclick="">Hausmann et al., 2010</a>)</span></p>
</div></aside></section>
<section id="immunological-mechanisms" class="slide level2 smaller">
<h2>Immunological mechanisms <br></h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/nejm2.png" class="lightbox" data-gallery="quarto-lightbox-gallery-16"><img data-src="images/nejm2.png" class="quarto-figure quarto-figure-center" width="500"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="castells.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Castells et al., 2019</a>)</span></p>
</div></aside></section></section>
<section>
<section id="penicillin-allergy" class="title-slide slide level1" data-background-color="#9B0014">
<h1>Penicillin allergy</h1>

</section>
<section id="penicillin-allergy-epidemiology" class="slide level2">
<h2>Penicillin allergy epidemiology</h2>
<p><br></p>
<ul>
<li class="fragment"><p>10-20% of patients will report a history of an allergy to PCN therapy&nbsp;</p></li>
<li class="fragment"><p>However, only 0.5%-2% of all PCN administrations actually result in hypersensitivity reactions, most often rash&nbsp;</p>
<ul>
<li class="fragment">Of these 1% are IgE mediated&nbsp;</li>
</ul></li>
<li class="fragment"><p>The incidence IgE PCN allergies is decreasing, partially due to the reduced use of parenteral PCN, which degradation products in solution may be the primary culprit&nbsp;</p></li>
<li class="fragment"><p>Statistics from the UK 1972-2007 oral amoxicillin:</p>
<ul>
<li class="fragment">1 death after anaphylaxis with oral amoxicillin (35 years and 100 million treatment courses)</li>
</ul></li>
<li class="fragment"><p>Most reports of penicillin allergy describe unknown or cutaneous reaction</p></li>
</ul>
<p><br></p>
</section>
<section id="public-health-implications" class="slide level2 smaller">
<h2>Public health implications</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/public.png" class="lightbox" data-gallery="quarto-lightbox-gallery-17"><img data-src="images/public.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="castells.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Castells et al., 2019</a>)</span></p>
</div></aside></section>
<section id="so-if-a-patient-reports-they-have-a-penicillin-allergy" class="slide level2 smaller">
<h2>So if a patient reports they have a <br> penicillin allergy…</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<p><strong>5% need allergy evaluation</strong></p>
<ul>
<li><p>Recent history if true IgE type reaction</p></li>
<li><p>Blistering rash</p></li>
<li><p>Hemolytic anemia</p></li>
<li><p>Nephritis</p></li>
<li><p>Hepatitis</p></li>
<li><p>Fever and joint pain</p></li>
<li><p>Severe cutaneous adverse reaction (SCAR)</p></li>
</ul>
</div><div class="column" style="width:50;">
<p><strong>95% can tolerate penicillins</strong></p>
<ul>
<li>Delayed, benign rash (Type IV reaction) that often does not recur with rechallenge</li>
<li>True IgE reactions wane over time, with 80% becoming tolerant after 10 years&nbsp;</li>
<li>Many patients were never allergic, but had other symptoms they though represented a PCN allergy (concurrent viral infection, GI distress)</li>
</ul>
</div></div>
</section>
<section id="top-4-patient-penicillin-allergy-myths" class="slide level2" data-background-image="images/amoxicillin.png" data-background-opacity="0.1">
<h2>Top 4 patient penicillin allergy myths</h2>
<p><br></p>
<ul>
<li class="fragment"><p><strong>Once you have an penicillin allergy, you have it for life</strong></p>
<ul>
<li class="fragment">Allergy wanes over time, 80% of patients with type I (IgE-mediated reactions) will not have an allergy after a 10 year period</li>
</ul></li>
<li class="fragment"><p><strong>Viral rashes mistaken for antibiotic therapy</strong></p>
<ul>
<li class="fragment"><p>E.g., child with a viral exanthematous rash treated with a course of penicillin</p></li>
<li class="fragment"><p>Pediatric studies have reported &gt;90% of children who developed rashes on antibiotic therapy do not develop a rash when rechallenged with penicillin again</p></li>
</ul></li>
<li class="fragment"><p><strong>Adverse effects mistaken by the patient as drug allergy</strong></p>
<ul>
<li class="fragment">E.g. diarrhea, stomach cramps</li>
</ul></li>
<li class="fragment"><p><strong>“I have a family history of penicillin allergy”</strong></p>
<ul>
<li class="fragment">No genetic basis has been identified for penicillin allergies</li>
</ul></li>
</ul>
</section>
<section id="penicillin-allergy-history" class="slide level2">
<h2>Penicillin allergy history</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/history.png" class="lightbox" data-gallery="quarto-lightbox-gallery-18"><img data-src="images/history.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<p><br></p>
<aside><div>
<p><span class="citation" data-cites="shenoy.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Shenoy et al., 2019</a>)</span></p>
</div></aside></section>
<section id="timing-and-clinical-presentation-of-reaction" class="slide level2">
<h2>Timing and clinical presentation of reaction</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/contraindications.png" class="lightbox" data-gallery="quarto-lightbox-gallery-19"><img data-src="images/contraindications.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="shenoy.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Shenoy et al., 2019</a>)</span></p>
</div></aside></section>
<section id="how-to-assess-patient-risk" class="slide level2">
<h2>How to assess patient risk</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/risk.png" class="lightbox" data-gallery="quarto-lightbox-gallery-20"><img data-src="images/risk.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="shenoy.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Shenoy et al., 2019</a>)</span></p>
</div></aside></section>
<section id="penfast-score" class="slide level2 smaller">
<h2>PENFAST score</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/penfast.png" class="lightbox" data-gallery="quarto-lightbox-gallery-21"><img data-src="images/penfast.png" class="quarto-figure quarto-figure-center" width="500"></a></p>
</figure>
</div>

<aside><div>
<p>The PEN-FAST clinical decision rule for patients reporting a penicillin allergy uses 3 clinical criteria of time from penicillin allergy episode, phenotype, and treatment required. A total score is calculated using PEN-FAST score in the upper panel,and interpretation for risk strategy is provided in the lower panel. <sup>a</sup>Includes unknown. <sup>b</sup>Forms of severe delayed reactions include potential Stevens-Johnson syndrome, toxic epidermalnecrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalizedexanthematous pustulosis. Patients with a severe delayed rash with mucosal involvement should be considered to have a severe cutaneous adverse reaction. Acute interstitial nephritis, drug induced liver injury, serum sickness and isolated drug fever were excluded phenotypes from the derivation and validation cohorts.</p>
<p><span class="citation" data-cites="trubiano.etal_2020">(<a href="#/references" role="doc-biblioref" onclick="">Trubiano et al., 2020</a>)</span></p>
</div></aside></section>
<section id="penfast-performance" class="slide level2">
<h2>PENFAST performance</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/penfast_perf.png" class="lightbox" data-gallery="quarto-lightbox-gallery-22"><img data-src="images/penfast_perf.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="trubiano.etal_2020">(<a href="#/references" role="doc-biblioref" onclick="">Trubiano et al., 2020</a>)</span></p>
</div></aside></section>
<section id="direct-oral-amoxicillin-challenge" class="slide level2">
<h2>Direct oral amoxicillin challenge</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/amox_challenge.png" class="lightbox" data-gallery="quarto-lightbox-gallery-23"><img data-src="images/amox_challenge.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="macy.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Macy et al., 2023</a>)</span></p>
</div></aside></section>
<section id="rationale-behind-oral-amoxicillin-challenge" class="slide level2">
<h2>Rationale behind oral amoxicillin challenge</h2>
<p><br></p>
<ul>
<li>Only ∼2% of penicillin “allergic” individuals develop an acute hypersensitivity reaction with an oral challenge of a therapeutic dose and 1 hour of observation.
<ul>
<li>An additional approximately 2% will have a delayed onset, typically benign, rash within the next 5 days.</li>
<li>The requirement for viral costimulation of T cells likely explains the low reproducibility of drug exanthems.</li>
</ul></li>
<li>Hence, a direct oral challenge with a single therapeutic dose of amoxicillin is an important step to avoid unnecessary penicillin allergy labels, and indicated in low-risk phenotypes and nonanaphylactic symptoms, such as those with benign delayed-onset rashes without systemic symptoms or SCAR features</li>
</ul>
</section>
<section id="palace-study" class="slide level2">
<h2>Palace study</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/Palace.png" class="lightbox" data-gallery="quarto-lightbox-gallery-24"><img data-src="images/Palace.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="copaescu.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Copaescu et al., 2023</a>)</span></p>
</div></aside></section>
<section id="two-step-oral-amoxicillin-challenge" class="slide level2">
<h2>Two step oral amoxicillin challenge</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/2step.png" class="lightbox" data-gallery="quarto-lightbox-gallery-25"><img data-src="images/2step.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="macy.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Macy et al., 2023</a>)</span></p>
</div></aside></section>
<section id="anaphylaxis-medications" class="slide level2">
<h2>Anaphylaxis medications</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/anaphylaxis.png" class="lightbox" data-gallery="quarto-lightbox-gallery-26"><img data-src="images/anaphylaxis.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="macy.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Macy et al., 2023</a>)</span></p>
</div></aside></section>
<section id="how-to-assess-patient-risk-1" class="slide level2">
<h2>How to assess patient risk</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/risk.png" class="lightbox" data-gallery="quarto-lightbox-gallery-27"><img data-src="images/risk.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="shenoy.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Shenoy et al., 2019</a>)</span></p>
</div></aside></section>
<section id="skin-testing" class="slide level2">
<h2>Skin testing</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/skintest.png" class="lightbox" data-gallery="quarto-lightbox-gallery-28"><img data-src="images/skintest.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="macy.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Macy et al., 2023</a>)</span></p>
</div></aside></section>
<section id="allergic-determinates" class="slide level2 smaller">
<h2>Allergic determinates</h2>
<div class="columns">
<div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/penicillins.png" class="lightbox" data-gallery="quarto-lightbox-gallery-29"><img data-src="images/penicillins.png" class="quarto-figure quarto-figure-center" width="150"></a></p>
</figure>
</div>
</div><div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/minor.png" class="lightbox" data-gallery="quarto-lightbox-gallery-30"><img data-src="images/minor.png" class="quarto-figure quarto-figure-center" width="150"></a></p>
</figure>
</div>
</div></div>

<aside><div>
<p><span class="citation" data-cites="castells.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Castells et al., 2019</a>)</span></p>
</div></aside></section>
<section id="penicillin-skin-test-assessment" class="slide level2">
<h2>Penicillin skin test assessment</h2>
<ul>
<li><p>High negative predictive value (NPV) ~95% for IgE-mediated reactions</p></li>
<li><p>Poor positive-predictive value- Possible false positive diagnosis if used in patient with low pre-test probability</p></li>
<li><p>Amoxicillin is commonly used to challenge after negative penicillin skin tests as it addresses the core β-lactam of penicillin and also side-chain–specific reactions, which may not be detected through skin testing with penicillin itself (NPV 100% if both are negative)</p></li>
<li><p>Traditional penicillin skin testing or amoxicillin challenge may be negative in patients with historical reactivity to piperacillin-tazobactam. Skin testing to piperacillin-tazobactam may help to establish this selective sensitization, and these patients are often able to tolerate other penicillins</p></li>
<li><p>Penicillin skin testing has no value in delayed reactions, including SJS/TEN, DRESS, and other noncutaneous organ-based reactions</p></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="macy.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Macy et al., 2023</a>)</span></p>
</div></aside></section>
<section id="penicillin-skin-test-assessment-1" class="slide level2">
<h2>Penicillin skin test assessment</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/skintest2.png" class="lightbox" data-gallery="quarto-lightbox-gallery-31"><img data-src="images/skintest2.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="macy.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Macy et al., 2023</a>)</span></p>
</div></aside></section>
<section id="penicillin-skin-test-assessment--medium-risk-history" class="slide level2 smaller">
<h2>Penicillin skin test assessment <br> -Medium risk history</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/medium%20risk.png" class="lightbox" data-gallery="quarto-lightbox-gallery-32"><img data-src="images/medium%20risk.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="macy.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Macy et al., 2023</a>)</span></p>
</div></aside></section>
<section id="impact-medium-risk-patients" class="slide level2">
<h2>Impact “medium risk” patients?</h2>
<p><br></p>
<ul>
<li class="fragment">A negative skin test is associated with a 95% NPV for PCN allergy</li>
<li class="fragment">A negative skin test plus negative amoxicillin challenge approaches 100% NPV for PCN allergy</li>
<li class="fragment">If skin test is positive, amoxicillin challenge is not considered</li>
<li class="fragment">Patient should be referred to an allergy/immunologist or desensitization considered</li>
</ul>
</section>
<section id="desensitization" class="slide level2">
<h2>Desensitization</h2>
<p><br></p>
<ul>
<li class="fragment">Progressive, graded de-granulation of mast cells (histamine release) and internalization of high-affinity IgE receptors by administering graded doses of antibiotic</li>
<li class="fragment">Desensitization is contraindicated in patients with a history of a penicillin-induced exfoliative dermatitis, Stevens-Johnson syndrome, or toxic epidermal necrolysis</li>
<li class="fragment">Desensitization has no effect on the incidence of non-IgE mediated reactions such as serum sickness, hemolytic anemia, maculopapular rashes, drug fever, hepatitis, or interstitial nephritis</li>
<li class="fragment">If the patient does not receive a dose for a period of more than 24 hours, the risk for an immediate IgE-mediated reaction can be restored and repeat desensitization is required if the same drug is to be used again</li>
</ul>
</section>
<section id="sample-desensitization-protocol" class="slide level2">
<h2>Sample desensitization protocol</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/meropenem.png" class="lightbox" data-gallery="quarto-lightbox-gallery-33"><img data-src="images/meropenem.png" class="quarto-figure quarto-figure-center" width="400"></a></p>
</figure>
</div>

<aside><div>
<p>Source: MD Anderson Cancer Center, Houston, Texas</p>
</div></aside></section>
<section id="other-desensitization-protocols" class="slide level2">
<h2>Other desensitization protocols</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/Sanford.png" class="lightbox" data-gallery="quarto-lightbox-gallery-34"><img data-src="images/Sanford.png" class="quarto-figure quarto-figure-center" width="200"></a></p>
</figure>
</div>
</section>
<section id="cross-reactivity-infectious-diseases-dogma" class="slide level2">
<h2>Cross-reactivity: Infectious diseases dogma</h2>
<p><br></p>
<ul>
<li>Common teaching: If a patient has a documented PCN allergy, the risk of cross reactions with cephalosporins is 10%</li>
<li><strong>THIS IS FALSE,</strong> the actual cross reactivity is more likely 2%-3%
<ul>
<li>A subset of patients with history of anaphylaxis may have cross-reactivity determined by the R1 sidechain of the molecule</li>
<li>Cefazolin as a unique side chain and and very low risk for cross-reactivity</li>
</ul></li>
</ul>
</section>
<section id="risk-of-cross-reactivity-related-to-cephalosporin-sidechain" class="slide level2">
<h2>Risk of cross-reactivity related to cephalosporin sidechain</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/cross-reactivity.png" class="lightbox" data-gallery="quarto-lightbox-gallery-35"><img data-src="images/cross-reactivity.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>

<aside><div>
<p>Source: Stanford University Hospital Antimicrobial Stewardship</p>
</div></aside></section>
<section id="β-lactams-with-common-side-chains" class="slide level2">
<h2>β-lactams with common side chains</h2>
<p><br></p>
<p><a href="images/sidechains.png" class="lightbox" data-gallery="quarto-lightbox-gallery-36"><img data-src="images/sidechains.png"></a></p>
</section>
<section id="cephtest-application-of-penfast-score-to-cephalosporin-allergies" class="slide level2">
<h2>CEPHTEST: Application of PENFAST <br> score to cephalosporin allergies</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/cephfast.png" class="lightbox" data-gallery="quarto-lightbox-gallery-37"><img data-src="images/cephfast.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>
</section>
<section id="what-is-the-cross-reactivity-with-carbapenems" class="slide level2">
<h2>What is the cross-reactivity with carbapenems?</h2>
<p><br></p>
<ul>
<li>Cross reactivity with penicillin allergy and carbapenems is less than 1%</li>
<li>No cross reactivity between penicillins and monobactams (aztreonam)</li>
<li>A graded challenge or test dose can be considered:
<ul>
<li>i.e.&nbsp;Infuse 5-10% of dose and observe patient, then progress to full dose if not reaction</li>
<li>Skin testing (if available) could also rule out allergies</li>
</ul></li>
</ul>
</section>
<section id="special-populations-that-should-be-considered-for-testing" class="slide level2 smaller">
<h2>Special populations that should be <br> considered for testing</h2>
<p><br></p>
<ul>
<li><strong>Peri-procedure before elective surgery</strong>
<ul>
<li>Importance of antibiotic timing/tissue levels at time of incision-less optimal with vancomycin that requires longer infusion</li>
</ul></li>
<li><strong>Pregnancy</strong>
<ul>
<li>PCN allergy associated with increased risk of cesarean delivery, post-cesarean wound complications, and longer length of stay</li>
<li>Consider third trimester referral for testing in patients with planned cesarean delivery, group B streptococcus colonization</li>
</ul></li>
<li><strong>Long term care facilities</strong>
<ul>
<li>Non-beta-lactam based therapies have higher risk for drug interactions</li>
<li>Higher risk for adverse effects</li>
</ul></li>
<li><strong>Hematology-oncology</strong>
<ul>
<li>Consider testing before chemotherapy or transplant (onset of of immunosuppression)</li>
</ul></li>
<li><strong>STD clinics</strong></li>
<li><strong>ICU patients?</strong></li>
</ul>
</section></section>
<section>
<section id="non-penicillin-allergies" class="title-slide slide level1" data-background-color="#9B0014">
<h1>Non-penicillin allergies</h1>

</section>
<section id="similar-principles--patient-history-is-key" class="slide level2">
<h2>Similar principles- patient history is key</h2>
<p><br></p>
<ul>
<li>Which drugs was the patient taking?</li>
<li>Dates of intake</li>
<li>Exact sequence of events</li>
<li>Underlying disease/Concomitant infections</li>
<li>Other drug administered at the same time/concomitant infections</li>
<li>Clinical morphology (at several time points)of rash</li>
<li>Histology of eosinophilia?</li>
</ul>
</section>
<section id="intradermal-testing-non-beta-lactams" class="slide level2 smaller">
<h2>Intradermal testing-Non beta-lactams</h2>
<div class="columns">
<div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/intradermal.png" class="lightbox" data-gallery="quarto-lightbox-gallery-38"><img data-src="images/intradermal.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>
</div><div class="column" style="width:50%;">
<ul>
<li>Skin tests for most antimicrobial agents lack high negative predictive values, and skin test positivity is often a function of the time elapsed since the index reaction</li>
<li>Prick and intradermal tests less well standardized- non-irritating formulations required</li>
<li>Some antibiotics are irritating even at low concentrations, making testing difficult</li>
<li>Special cellular activation tests may be available in some centers for some drugs
<ul>
<li>e.g., The BAT (flow cytometry) detects the upregulation of activation markers CD63 and CD203c on the surface of basophils after incubation with the implicated drug</li>
</ul></li>
</ul>
</div></div>

<aside><div>
<p>Image: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel</p>
</div></aside></section>
<section id="approach-to-delayed-type-hypersensitivity-testing" class="slide level2">
<h2>Approach to delayed-type <br> hypersensitivity testing</h2>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/Patch.png" class="lightbox" data-gallery="quarto-lightbox-gallery-39"><img data-src="images/Patch.png" width="800"></a></p>
</div><div class="column" style="width:50%;">
<ul>
<li>Intradermal or patch testing with reading 24-72 hours
<ul>
<li>Low sensitivity, high specificity</li>
</ul></li>
<li>Lymphocyte transformation testing
<ul>
<li>Available in specialized laboratories</li>
<li>Haptenization to become an antigen in vivo (hard to imitate in lab)</li>
</ul></li>
</ul>
</div></div>

<aside><div>
<p>Image: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel</p>
</div></aside></section>
<section id="sulfonamide-hypersensitivity" class="slide level2">
<h2>Sulfonamide hypersensitivity</h2>
<p><br></p>
<ul>
<li>Incidence 8%</li>
<li>Primarily cutaneous and GI tract</li>
<li>Only 3% are considered true hypersensitivity reactions.
<ul>
<li>Most common presentations are limited exanthems and fixed drug eruptions</li>
<li>However…sulfonamides are disproportionately associated with infrequent severe side effects (i.e.&nbsp;TEN, Stevens-Johnson Syndrome)</li>
</ul></li>
<li>Mechanisms IgE-mediated are known to occur, but other poorly understood direct T-cell mediated mechanisms are more likely to be responsible</li>
<li>Higher incidence of reactions in patients with HIV/AIDS, tuberculosis</li>
</ul>
</section>
<section id="mechanism-of-sulfonamide-hypersensitivity" class="slide level2 smaller">
<h2>Mechanism of sulfonamide hypersensitivity</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/sulfallergy.png" class="lightbox" data-gallery="quarto-lightbox-gallery-40"><img data-src="images/sulfallergy.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="slatore.tilles_2004">(<a href="#/references" role="doc-biblioref" onclick="">Slatore and Tilles, 2004</a>)</span></p>
</div></aside></section>
<section id="penfast-score-applied-to-sulfa-allergies" class="slide level2">
<h2>PENFAST score applied to sulfa allergies</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/sulfast.png" class="lightbox" data-gallery="quarto-lightbox-gallery-41"><img data-src="images/sulfast.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="waldron.etal_2023">(<a href="#/references" role="doc-biblioref" onclick="">Waldron et al., 2023</a>)</span></p>
</div></aside></section>
<section id="non-sensitizing-allergic-reactions" class="slide level2">
<h2>Non-sensitizing allergic reactions</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/receptors.png" class="lightbox" data-gallery="quarto-lightbox-gallery-42"><img data-src="images/receptors.png"></a></p>
</div><div class="column" style="width:50%;">
<ul>
<li>Mas-related G protein coupled receptor (MRGPRX2)</li>
<li>Neuromuscular blocking agents</li>
<li>Opioids</li>
<li>Radiocontrast media</li>
<li>Vancomycin, glycopeptides, fluoroquinolones</li>
<li>Complement-activation-related pseudoallergy (CARPA)</li>
<li>Liposomes, drug carriers</li>
</ul>
</div></div>

<aside><div>
<p><span class="citation" data-cites="ebo.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Ebo et al., 2019</a>)</span></p>
</div></aside></section>
<section id="vancomycin-infusion-reaction-red-man-syndrome" class="slide level2">
<h2>Vancomycin infusion reaction <br> “red man syndrome”</h2>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/redman.png" class="lightbox" data-gallery="quarto-lightbox-gallery-43"><img data-src="images/redman.png"></a></p>
</div><div class="column" style="width:50%;">
<ul>
<li>Vancomycin can also cause:
<ul>
<li>Hypotension, anaphylaxis</li>
<li>Maculopapular exanthems</li>
<li>Vasculitis E</li>
<li>Eosinophilia Exfoliative dermatitis/DRESS/Stephens-Johnson</li>
</ul></li>
</ul>
</div></div>

<aside><div>
<p><span class="citation" data-cites="alvarez-arango.etal_2021">(<a href="#/references" role="doc-biblioref" onclick="">Alvarez-Arango et al., 2021</a>)</span></p>
</div></aside></section>
<section id="take-home-messages" class="slide level2">
<h2>Take home messages</h2>
<p><br></p>
<ul>
<li>Penicillin allergies are the most common “contraindication” to antibiotic therapy, but most histories do not represent true allergies</li>
<li>A systematic approach can be used to evaluate and potentially “de-label” patients with penicillin allergy</li>
<li>Cross-reactivity rates are low with current cephalosporins and carbapenems, but can alternatively be addressed through antibiotic challenges and skin testing</li>
<li>Desensitization can be attempted in specific cases when a particular antibiotic is needed for IgE-mediated reactions</li>
<li>Some antibiotics cause non-immune-related hypersensitivity reactions that can be managed by slowing infusions and administering antihistamines</li>
</ul>
</section>
<section id="references" class="slide level2 smaller scrollable">
<h2>References</h2>
<p><br></p>

<div id="refs" class="references csl-bib-body" data-entry-spacing="0" role="list">
<div id="ref-alvarez-arango.etal_2021" class="csl-entry" role="listitem">
Alvarez-Arango S, Ogunwole SM, Sequist TD, Burk CM, Blumenthal KG. Vancomycin infusion reaction — moving beyond <span>“red man syndrome.”</span> New England Journal of Medicine 2021;384:1283–6. <a href="https://doi.org/10.1056/NEJMp2031891">https://doi.org/10.1056/NEJMp2031891</a>.
</div>
<div id="ref-castells.etal_2019" class="csl-entry" role="listitem">
Castells M, Khan DA, Phillips EJ. Penicillin allergy. New England Journal of Medicine 2019;381:2338–51. <a href="https://doi.org/10.1056/NEJMra1807761">https://doi.org/10.1056/NEJMra1807761</a>.
</div>
<div id="ref-copaescu.etal_2023" class="csl-entry" role="listitem">
Copaescu AM, Vogrin S, James F, Chua KYL, Rose MT, De Luca J, et al. Efficacy of a clinical decision rule to enable direct oral challenge in patients with low-risk penicillin allergy: The PALACE randomized clinical trial. JAMA Internal Medicine 2023;183:944–52. <a href="https://doi.org/10.1001/jamainternmed.2023.2986">https://doi.org/10.1001/jamainternmed.2023.2986</a>.
</div>
<div id="ref-ebo.etal_2019" class="csl-entry" role="listitem">
Ebo DG, Clarke RC, Mertes P-M, Platt PR, Sabato V, Sadleir PHM. Molecular mechanisms and pathophysiology of perioperative hypersensitivity and anaphylaxis: A narrative review. British Journal of Anaesthesia 2019;123:e38–49. <a href="https://doi.org/10.1016/j.bja.2019.01.031">https://doi.org/10.1016/j.bja.2019.01.031</a>.
</div>
<div id="ref-hausmann.etal_2010" class="csl-entry" role="listitem">
Hausmann O, Schnyder B, Pichler WJ. Drug hypersensitivity reactions involving skin. In: Uetrecht J, editor. Adverse drug reactions, Springer; 2010, p. 29–55. <a href="https://doi.org/10.1007/978-3-642-00663-0_2">https://doi.org/10.1007/978-3-642-00663-0_2</a>.
</div>
<div id="ref-macy.etal_2023" class="csl-entry" role="listitem">
Macy E, Trautmann A, Chiriac AM, Demoly P, Phillips EJ. Advances in the understanding of drug hypersensitivity: 2012 through 2022. The Journal of Allergy and Clinical Immunology: In Practice 2023;11:80–91. <a href="https://doi.org/10.1016/j.jaip.2022.10.025">https://doi.org/10.1016/j.jaip.2022.10.025</a>.
</div>
<div id="ref-shenoy.etal_2019" class="csl-entry" role="listitem">
Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: A review. JAMA: The Journal of the American Medical Association 2019;321:188–99. <a href="https://doi.org/10.1001/jama.2018.19283">https://doi.org/10.1001/jama.2018.19283</a>.
</div>
<div id="ref-slatore.tilles_2004" class="csl-entry" role="listitem">
Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunology and Allergy Clinics of North America 2004;24:477–90, vii. <a href="https://doi.org/10.1016/j.iac.2004.03.011">https://doi.org/10.1016/j.iac.2004.03.011</a>.
</div>
<div id="ref-trubiano.etal_2020" class="csl-entry" role="listitem">
Trubiano JA, Vogrin S, Chua KYL, Bourke J, Yun J, Douglas A, et al. Development and validation of a penicillin allergy clinical decision rule. JAMA Internal Medicine 2020;180:745–52. <a href="https://doi.org/10.1001/jamainternmed.2020.0403">https://doi.org/10.1001/jamainternmed.2020.0403</a>.
</div>
<div id="ref-waldron.etal_2023" class="csl-entry" role="listitem">
Waldron JL, Rose M, Vogrin S, Krantz MS, Bolotte R, Phillips EJ, et al. Development and validation of a sulfa antibiotic allergy clinical decision rule. JAMA Network Open 2023;6:e2316776. <a href="https://doi.org/10.1001/jamanetworkopen.2023.16776">https://doi.org/10.1001/jamanetworkopen.2023.16776</a>.
</div>
<div id="ref-zhang.liu_2015" class="csl-entry" role="listitem">
Zhang Z, Liu X. Acute generalized exanthematous pustulosis. New England Journal of Medicine 2015;372:161–1. <a href="https://doi.org/10.1056/NEJMicm1401196">https://doi.org/10.1056/NEJMicm1401196</a>.
</div>
</div>
</section></section>
    </div>
  <div class="quarto-auto-generated-content" style="display: none;">
<div class="footer footer-default">

</div>
</div></div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="Lecture1_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="Lecture1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="Lecture1_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': false,
'previewLinksAuto': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'jumpToSlide': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleScrollView(event)\"><kbd>r</kbd> Scroll View Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"5\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: true,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: 'c/t',

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'fade',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'fast',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdn.jsdelivr.net/npm/mathjax@2.7.9/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
      window.document.addEventListener("DOMContentLoaded", function (event) {
        const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
        tabsets.forEach(function(tabset) {
          const tabby = new Tabby('#' + tabset.id);
        });
        const isCodeAnnotation = (el) => {
          for (const clz of el.classList) {
            if (clz.startsWith('code-annotation-')) {                     
              return true;
            }
          }
          return false;
        }
        const onCopySuccess = function(e) {
          // button target
          const button = e.trigger;
          // don't keep focus
          button.blur();
          // flash "checked"
          button.classList.add('code-copy-button-checked');
          var currentTitle = button.getAttribute("title");
          button.setAttribute("title", "Copied!");
          let tooltip;
          if (window.bootstrap) {
            button.setAttribute("data-bs-toggle", "tooltip");
            button.setAttribute("data-bs-placement", "left");
            button.setAttribute("data-bs-title", "Copied!");
            tooltip = new bootstrap.Tooltip(button, 
              { trigger: "manual", 
                customClass: "code-copy-button-tooltip",
                offset: [0, -8]});
            tooltip.show();    
          }
          setTimeout(function() {
            if (tooltip) {
              tooltip.hide();
              button.removeAttribute("data-bs-title");
              button.removeAttribute("data-bs-toggle");
              button.removeAttribute("data-bs-placement");
            }
            button.setAttribute("title", currentTitle);
            button.classList.remove('code-copy-button-checked');
          }, 1000);
          // clear code selection
          e.clearSelection();
        }
        const getTextToCopy = function(trigger) {
          const outerScaffold = trigger.parentElement.cloneNode(true);
          const codeEl = outerScaffold.querySelector('code');
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
        const clipboard = new window.ClipboardJS('.code-copy-button:not([data-in-quarto-modal])', {
          text: getTextToCopy
        });
        clipboard.on('success', onCopySuccess);
        if (window.document.getElementById('quarto-embedded-source-code-modal')) {
          const clipboardModal = new window.ClipboardJS('.code-copy-button[data-in-quarto-modal]', {
            text: getTextToCopy,
            container: window.document.getElementById('quarto-embedded-source-code-modal')
          });
          clipboardModal.on('success', onCopySuccess);
        }
          var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
          var mailtoRegex = new RegExp(/^mailto:/);
            var filterRegex = new RegExp('/' + window.location.host + '/');
          var isInternal = (href) => {
              return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
          }
          // Inspect non-navigation links and adorn them if external
         var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool):not(.about-link)');
          for (var i=0; i<links.length; i++) {
            const link = links[i];
            if (!isInternal(link.href)) {
              // undo the damage that might have been done by quarto-nav.js in the case of
              // links that we want to consider external
              if (link.dataset.originalHref !== undefined) {
                link.href = link.dataset.originalHref;
              }
            }
          }
        function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
          const config = {
            allowHTML: true,
            maxWidth: 500,
            delay: 100,
            arrow: false,
            appendTo: function(el) {
                return el.closest('section.slide') || el.parentElement;
            },
            interactive: true,
            interactiveBorder: 10,
            theme: 'light-border',
            placement: 'bottom-start',
          };
          if (contentFn) {
            config.content = contentFn;
          }
          if (onTriggerFn) {
            config.onTrigger = onTriggerFn;
          }
          if (onUntriggerFn) {
            config.onUntrigger = onUntriggerFn;
          }
            config['offset'] = [0,0];
            config['maxWidth'] = 700;
          window.tippy(el, config); 
        }
        const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
        for (var i=0; i<noterefs.length; i++) {
          const ref = noterefs[i];
          tippyHover(ref, function() {
            // use id or data attribute instead here
            let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
            try { href = new URL(href).hash; } catch {}
            const id = href.replace(/^#\/?/, "");
            const note = window.document.getElementById(id);
            if (note) {
              return note.innerHTML;
            } else {
              return "";
            }
          });
        }
        const findCites = (el) => {
          const parentEl = el.parentElement;
          if (parentEl) {
            const cites = parentEl.dataset.cites;
            if (cites) {
              return {
                el,
                cites: cites.split(' ')
              };
            } else {
              return findCites(el.parentElement)
            }
          } else {
            return undefined;
          }
        };
        var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
        for (var i=0; i<bibliorefs.length; i++) {
          const ref = bibliorefs[i];
          const citeInfo = findCites(ref);
          if (citeInfo) {
            tippyHover(citeInfo.el, function() {
              var popup = window.document.createElement('div');
              citeInfo.cites.forEach(function(cite) {
                var citeDiv = window.document.createElement('div');
                citeDiv.classList.add('hanging-indent');
                citeDiv.classList.add('csl-entry');
                var biblioDiv = window.document.getElementById('ref-' + cite);
                if (biblioDiv) {
                  citeDiv.innerHTML = biblioDiv.innerHTML;
                }
                popup.appendChild(citeDiv);
              });
              return popup.innerHTML;
            });
          }
        }
      });
      </script>
    <script>var lightboxQuarto = GLightbox({"closeEffect":"zoom","descPosition":"bottom","loop":false,"openEffect":"zoom","selector":".lightbox"});
    (function() {
      let previousOnload = window.onload;
      window.onload = () => {
        if (previousOnload) {
          previousOnload();
        }
        lightboxQuarto.on('slide_before_load', (data) => {
          const { slideIndex, slideNode, slideConfig, player, trigger } = data;
          const href = trigger.getAttribute('href');
          if (href !== null) {
            const imgEl = window.document.querySelector(`a[href="${href}"] img`);
            if (imgEl !== null) {
              const srcAttr = imgEl.getAttribute("src");
              if (srcAttr && srcAttr.startsWith("data:")) {
                slideConfig.href = srcAttr;
              }
            }
          } 
        });
      
        lightboxQuarto.on('slide_after_load', (data) => {
          const { slideIndex, slideNode, slideConfig, player, trigger } = data;
          if (window.Quarto?.typesetMath) {
            window.Quarto.typesetMath(slideNode);
          }
        });
      
      };
      
    })();
              </script>
    

</body></html>